EnteroMedics to Host Conference Call after Presentation at the 25th Annual American Society for Metabolic and Bariatric Surgery Meeting; Company to present study data and update EMPOWER trial enrollment.

ST. PAUL, Minn. -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that it expects study results from ongoing clinical trials of the company's VBLOC[TM] vagal blocking therapy to be presented at 3:00 PM ET on June 19, 2008 during a plenary session of the 25th annual meeting of the American Society for Metabolic and Bariatric Surgery, being held June 15-20 in Washington, D.C. The oral presentation will include interim 12-month and updated 9-month excess weight loss, or EWL, endpoints from EnteroMedics' VBLOC-RF2 feasibility study for obesity therapy as well as a preliminary report on the Company's VBLOC-RC (rechargeable) device.

The company will host a conference call and live webcast at 4:30 PM EDT on Thursday, June 19, 2008 following the oral presentation, to discuss findings from the data presented at the meeting and provide an update on enrollment in the EMPOWER pivotal trial. To listen to the conference call, dial [phone] (United States and Canada) or [phone] (international), and use participant code (48663172) approximately 10 minutes prior to the start time. An audio replay of the conference call can be accessed by calling [phone] or [phone]. The replay will be available for 3 months. To access the live webcast, visit the investor relations section of EnteroMedics' website at www.enteromedics.com. A replay of the webcast will be available immediately after the conference call.

About VBLOC Therapy

EnteroMedics developed VBLOC[TM] vagal blocking therapy to offer bariatric surgeons and their patients a less invasive alternative to existing surgical weight loss procedures that may present significant risks and alter digestive system anatomy, lifestyle and food choices. VBLOC Therapy is delivered via the Maestro[TM] System through laparoscopically implanted leads to intermittently block the vagus nerves using high-frequency, low energy electrical impulses. VBLOC Therapy is designed to target the multiple digestive functions under control of the vagus nerves and to affect the perception of hunger and fullness.

About EnteroMedics Inc.

EnteroMedics is a development stage medical device company focused on the design and development of devices that use neuroblocking technology to treat obesity and other gastrointestinal disorders. EnteroMedics' proprietary neuroblocking technology, VBLOC[TM] vagal blocking therapy, is designed to intermittently block the vagus nerve using high-frequency, low-energy, electrical impulses. EnteroMedics recently received an investigational device exemption (IDE) application approval from FDA for the pivotal trial of its initial product for the treatment of obesity, the Maestro[TM] System. For more information, visit www.enteromedics.com.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements about EnteroMedics Inc. Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations, our losses since inception and for the foreseeable future; our lack of regulatory approval for our Maestro[TM] System for the treatment of obesity; our inability to complete our EMPOWER pivotal trial and other clinical trials, or significant delays in the completion of our clinical trials; our ability to timely commercialize our Maestro System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our Maestro System; physician adoption of our Maestro System and VBLOC[TM] vagal blocking therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in the Company's Form 10-K dated March 13, 2008. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Caution-Investigational device. Limited by Federal law to investigational use.

The implantation procedure and usage of the Maestro[TM] System carry some risks, such as the risk generally associated with laparoscopic procedures and those related to treatment as described in the Empower clinical trial informed consent.